Following T-cell expansion, we performed co-culture assays to detect the ability of PBMCs or T-cell expanded PBMCs to kill 786-O RCC cells pretreated with 5 or 10 μM DCLK1-IN-1. This evidence concerns the gene CD44 and renal cell carcinoma.